Skip to content
Triangle logo TriangleGet started
← Testicular Cancer

HEALTH PROFESSIONAL · SOURCE READING

Poor Prognosis

Source: Testicular Cancer Treatment (PDQ®)–Health Professional Version, National Cancer Institute.

Source updated: May 16, 2025 · Captured 2026-09-09.

Selected source text with whitespace normalised. This Triangle page is not an NCI PDQ summary.

Context: Treatment Option Overview for Testicular Cancer

Nonseminoma:

Mediastinal primary, or

Nonpulmonary visceral metastases, or

For markers–any of:

For markers–any of:

AFP more than 10,000 ng/mL, or

For markers–any of:

Beta-hCG more than 50,000 IU/mL (10,000 ng/mL), or

For markers–any of:

LDH more than 10 × the upper limit of normal

A total of 16% to 26% of nonseminomas are poor prognosis. The 5-year PFS rate is 41%; the 5-year survival rate is 71%.

Seminoma:

No patients are classified as poor prognosis.

Preserved source evidence · Not medical advice